Loading…
← CockpitCompetitor Analysis › 688179.SS Shanghai Aladdin Biochemical Technology Co. Ltd. Class AOpen in the cockpit ↗

Shanghai Aladdin Biochemical Technology Co. Ltd. Class A688179.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Runs an e-commerce catalog selling laboratory reagents and fine chemicals to Chinese research labs.

≈ A Chinese Sigma-Aldrich (lab reagent catalog/e-commerce)Momentum laggard 9
Mkt cap
$736M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$27.8M
20-day average traded
Fwd P/E
27.4×
forward earnings
ROIC−WACC
+1.3 pp
WACC 10.5%
Hurdle
-7 pp
Req g minus delivered
Next earnings
154 days
21 Apr 2027
Close · CNYCN¥13.70
1D-2.7%
1W-10.5%
1M-20.7%
3M-37.4%
6M-37.4%
YTD+9.7%
1Y+6.0%
ATR %7.7%
52w lowhigh56.7% off high

What Shanghai Aladdin Biochemical Technology does

Runs an e-commerce catalog selling laboratory reagents and fine chemicals to Chinese research labs.

Sells a very broad catalogue of reagents and chemicals through its website and marketplaces, with quick delivery to research labs, so orders are small but frequent and rely on repeat buyers. Products are a mix of items it makes itself and others it resells, and the own-made items carry better margins.

In one line: A Chinese Sigma-Aldrich (lab reagent catalog/e-commerce).

Products and services

  • Lab reagents/fine chemicals
  • Biochemical research products

Customers

  • University/research labs
  • Biotech/pharma R&D

Where it sits in the supply chain

  • Health Care
  • Life-science tools
  • Laboratory reagent/chemical e-commerce…

What could go right

  • China R&D/biotech spending growth

What could go wrong

  • Thin distribution/reagent margins
  • Import substitution competition

Moat: narrow (distribution, brand, installed base). Broad reagent catalog and e-commerce platform create convenience-driven repeat buying.

Headquarters: Shanghai, China · Founded: 2009 · Employees: 926

Named competitors

Shanghai Aladdin Biochemical Technology at a glance

Size Shanghai Aladdin Biochemical Technology (688179.SS) is a China Health Care company (Medical Specialties) with a market value of $736M, the 2780th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥13.70 on 18 Nov 2026.

Performance Over six months the shares fell 37.4%, against -13.5% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue grew 39.1% over the last twelve months (peer median +5.9%); the operating margin is 24.4% (peer median 11.4%).

Valuation It trades at 27.4× forward earnings against a peer median of 19.8× (4th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +24%, so the hurdle is -7 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.3 points above its cost of capital (10.5% WACC).

Next results Next results expected around 21 Apr 2027 (exchange calendar; dates can move).

Relative performance

7510012521 May 202621 Aug 202618 Nov 2026Peer median 88688179.SS 60
Six months, rebased to 100: Shanghai Aladdin Biochemical Technology against the median of its 20 peers (local-currency closes).

Shanghai Aladdin Biochemical Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥829MCN¥690MCN¥530MCN¥402MCN¥377M
Revenue growth—+30%+32%+7%—
Gross profitCN¥550MCN¥405MCN¥305MCN¥216MCN¥202M
EBITDAn/aCN¥215MCN¥170MCN¥118MCN¥115M
Net incomeCN¥143MCN¥102MCN¥98.8MCN¥85.8MCN¥92.8M
Free cash flowCN¥197MCN¥356MCN¥117MCN¥10.1M-CN¥105M
Capital expenditureCN¥6.22MCN¥49.0MCN¥35.5MCN¥45.7MCN¥62.0M
Total debtCN¥420MCN¥773MCN¥443MCN¥358MCN¥342M

Quarterly statements and history in the cockpit →

Shanghai Aladdin Biochemical Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%301367600855INMD6031083004530029503011223004633006222190688410VREX13027575CTKBMLAB301234BBNX688179.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai Aladdin Biochemical Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×200×400×301367INMD6031083004533011226881083004633006222190688410688179.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai Aladdin Biochemical Technology is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%301367INMD603108688108300463219068841013027575MLAB688179.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shanghai Aladdin Biochemical Technology is the large dot.

Shanghai Aladdin Biochemical Technology competitors and peer comparison

Head to head with its named competitors (688179.SS vs MRK.DE vs 688073.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shanghai Aladdin Biochemical Technology 688179.SS$736M-37%+39%24%27.4×17.1%
Merck KGaA MRK.DE$71.3B+16%+1%19%17.4×7.4%
Bide Pharmatech 688073.SS$801M+10%+10%19%24.3×13.9%

How Shanghai Aladdin Biochemical Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai Aladdin Biochemical Technology against its 20 peers (data as of 18 Nov 2026)
Measure688179.SSPeer medianRank in peer set
1-month return-20.7%-8.5%3rd lowest of 21
6-month return-37.4%-13.5%3rd lowest of 21
Distance from 52-week high-56.7%-37.6%3rd lowest of 21
Revenue growth (TTM)+39.1%+5.9%4th highest of 21
Operating margin24.4%11.4%2nd highest of 21
Forward P/E27.4×19.8×4th most expensive of 16
Growth the price implies (Req g, 7 yrs)17.1%5.9%5th most demanding of 15
Growth delivered (Del g)+24.2%+12.8%3rd highest of 15
Hurdle (Req g minus delivered)-7.2 pp-11.1 pp7th most demanding of 15
ROIC minus cost of capital+1.3 pp+1.3 pp11th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%27.4×17.1%+24.2%
BMC Medical 301367.SZChina$737M-17%+37%17%18.7×-1.5%+15.6%
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%n/an/an/a
InMode INMDUnited States$741M-8%+2%18%9.8×-10.8%+12.4%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%20.5×20.3%-0.2%
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%16.2×-1.9%+11.8%
Allmed Medical Products 002950.SZChina$747M-32%+14%8%n/an/an/a
Caina Technology 301122.SZChina$721M+36%+61%0%55.4×n/an/a
Sino Medical Sciences Technology 688108.SSChina$753M-41%+22%19%60.0×27.9%+9.9%
Maccura Biotechnology 300463.SZChina$756M-18%-1%-4%421.0×7.9%-10.2%
Doctorglasses Chain 300622.SZChina$710M-22%+6%14%22.8×-3.4%+15.7%
Zylox-Tonbridge Medical Technology 2190.HKHong Kong$768M-16%+39%25%14.4×3.8%+105.8%
SWS Hemodialysis Care 688410.SSChina$706M-11%+31%19%23.5×16.2%+25.9%
Varex Imaging VREXUnited States$771M+79%+5%8%19.9×n/an/a
LifeTech Scientific 1302.HKHong Kong$771M-30%+1%12%19.8×9.6%+15.5%
Japan Lifeline 7575.TJapan$703M+34%+6%19%14.5×-9.5%+2.9%
Cytek Biosciences CTKBUnited States$774M+57%+6%-21%n/an/an/a
Shanghai INT Medical Instruments 1501.HKHong Kong$700M-25%+35%21%15.9×-3.3%+23.5%
Mesa Laboratories MLABUnited States$775M+33%+2%10%11.5×21.3%+13.2%
Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZChina$697M+148%-14%3%n/a31.8%-0.6%
Beta Bionics BBNXUnited States$779M+42%+44%-73%n/an/an/a

Questions

Who are Shanghai Aladdin Biochemical Technology's main competitors?
Named competitors: Sigma-Aldrich (Merck KGaA) (MRK.DE), Bidepharm (688073.SS). The cockpit's measured peer set (industry) also includes BMC Medical (301367.SZ), Beijing Aerospace Changfeng (600855.SS), InMode (INMD), Shanghai Runda Medical Technology (603108.SS), Jiang Xi Sanxin Medtec (300453.SZ), Allmed Medical Products (002950.SZ).
Is Shanghai Aladdin Biochemical Technology expensive compared with its peers?
On forward p/e it trades at 27.4× against a peer median of 19.8×, 4th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +24%, so the hurdle is -7 pp: the price already allows for a slowdown.
How has Shanghai Aladdin Biochemical Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -37.4% against -13.5% for the median peer; over one year +6.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.